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Lifestyle modification offers a promising way of preventing or delaying Alzheimer’s disease 26 
(AD). In particular, nutritional interventions can contribute to decrease the risk of dementia. 27 
The efficacy of such interventions should be assessed in individuals thought to be prone to 28 
AD. It is therefore necessary to identify markers that may help detecting AD as early as 29 
possible. This review will focus on subtle neuropsychological changes that may already exist 30 
in the predementia phase, and that could point to individuals at risk of dementia. Episodic 31 
memory decline appears consistently as the earliest sign of incipient typical Alzheimer’s 32 
disease. An episodic memory test that ensures deep encoding of information and assesses 33 
retrieval with free as well as cued recall appears as a useful tool to detect patients at an early 34 
stage of AD. Beyond the memory domain, category verbal fluency has been shown to decline 35 
early and to predict progression to AD. Moreover, in line with current diagnosis criteria for 36 
prodromal Alzheimer’s disease, combining neuropsychological scores and neuroimaging data 37 
allows a better discrimination of future AD patients than neuroimaging or neuropsychological 38 
data alone. Altogether, the detection of cognitive changes that are predictive of the typical 39 
form of probable Alzheimer’s disease already in the predementia stage points to at risk people 40 
who are the best target for therapeutic interventions, such as nutrition or physical exercise 41 
counseling or dietary interventions. 42 
 43 
Keywords: Alzheimer’s disease, mild cognitive impairment, neuropsychology, early 44 
diagnosis.  45 
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Early neuropsychological detection of Alzheimer's disease 46 
 47 
Introduction 48 
Alzheimer’s disease (AD) is characterised by severe cognitive deficits, which worsen and 49 
affect an increasingly broad range of domains as the disease progresses. Although there exist 50 
some atypical forms starting with language, visuospatial or executive dysfunction, the most 51 
common syndromic presentation consists in memory impairment together with cognitive 52 
dysfunction in at least one other domain (language, reasoning, visuospatial abilities…) (1). 53 
Importantly, clinically evident dementia is preceded by a period lasting presumably one or 54 
more decades during which amyloid and tau proteins accumulate in the brain (2). Moreover, 55 
during the predementia period, cognitive deficits already exist. A recent study suggested that 56 
abnormal amyloid deposition could be detected about 17 years, hippocampal atrophy around 4 57 
years, and cognitive impairment 3 years before a clinical diagnosis of Alzheimer’s disease is 58 
made (3).  59 
Given that neuropathology has reached a critical point when dementia occurs, the 60 
predementia period is considered the best target for therapeutic interventions (e.g., (4)). 61 
Among possible interventions, besides pharmaceutical treatment, cognitive rehabilitation and 62 
lifestyle modifications appear as promising avenues for preventing or delaying dementia 63 
onset. In particular, lifestyle modifications, such as nutritional interventions, physical activity 64 
training and stimulating leisure activities, have received an increasing interest in recent years. 65 
They are thought to contribute to build a reserve allowing individuals to resist longer to 66 
Alzheimer neuropathology (5) and to reduce AD risk factors such as hypertension, obesity, 67 
diabetes, oxidative stress… For instance, healthy nutritional habits, including the consumption 68 
of omega-3-based fatty acids and antioxidant vitamins, seem to reduce the risk of dementia in 69 
late life (6-8). Moreover, interventions proposing the adoption of the Mediterranean diet, 70 
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sometimes in combination with supplement nutrients, may lead to an attenuation of cognitive 71 
decline (9-11). As these promising preventive and/or therapeutic approaches become 72 
available, future work should evaluate their efficacy in individuals who are in the predementia 73 
phase of Alzheimer’s disease.  74 
Currently, research on the detection of the earliest signs of Alzheimer’s disease points 75 
to several kinds of biomarkers: genetic biomarkers (e.g., APOEε4), neuroimaging biomarkers 76 
(e.g., cerebral atrophy, hypometabolism, amyloid deposition), cerebrospinal fluid (CSF) 77 
biomarkers (e.g., tau and amyloid levels) and cognitive markers (i.e., neuropsychological 78 
measures). In this review, we will focus on cognitive markers that may contribute to early 79 
detection of AD and hence to identify the best candidates to therapeutic interventions. It 80 
should be noted that the reviewed neuropsychological predictors apply to the typical form of 81 
Alzheimer’s disease, that is dementia with prominent and initial memory deficits (1). 82 
 83 
Review methods 84 
The process of selection of articles is illustrated in Figure 1. Articles dealing with predictors 85 
of Alzheimer’s disease were searched for by means of an initial Pubmed search with the 86 
following criteria and keywords: [(memory AND longitudinal AND Alzheimer's disease) 87 
AND (prodromal OR conversion OR preclinical)], [mild cognitive impairment AND 88 
(Alzheimer's disease OR dementia) AND neuropsychology AND (prediction OR 89 
longitudinal)], and [Alzheimer's disease AND conversion AND neuropsychology]. Further 90 
search through the bibliography of reviews and meta-analyses led to 84 additional 91 
publications focusing on neuropsychological predictors of dementia. After excluding 92 
references related to animal studies, non-Alzheimer dementia, treatment outcomes, 93 
cognitively normal individuals with APOE ε4 genotype and depression, we reviewed 216 94 
publications describing work on neuroimaging and/or neuropsychological indicators of 95 
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Alzheimer’s disease. From these, the current review included those that describe longitudinal 96 
assessments (i.e., involving at least 2 neuropsychological assessments over a follow-up period 97 
of minimum 1 year) of healthy older subjects or patients with mild cognitive impairment 98 
(MCI), with statistics evaluating the predictive power of neuropsychological measures in the 99 
discrimination between subjects who progress to Alzheimer’s disease and those who remained 100 
either cognitively normal or MCI. 101 
 102 
Approaches for early neuropsychological detection of dementia 103 
Two main approaches have been used to identify the cognitive markers of future development 104 
of Alzheimer’s disease, both having in common the reliance on longitudinal assessments of 105 
participants. Whereas one approach consists in population-based studies that follow large 106 
cohorts of community-dwelling normal older participants, the other focuses on patients with 107 
mild cognitive impairment. 108 
Large-scale population studies recruit healthy participants in the community and test 109 
them repeatedly with a more or less extensive neuropsychological battery. These longitudinal 110 
studies follow the participants for several years (e.g., from 4 years for the Bronx Aging Study 111 
(12) to 22 years for the Framingham study (13)). During the course of the follow-up, a 112 
proportion of the population develops Alzheimer’s disease. It is therefore possible to identify 113 
the cognitive functions that were impaired in the prodromal phase in the future AD patients in 114 
comparison to participants who remained normal, and hence to picture the chronological 115 
sequence of these cognitive impairments (14, 15). Alternatively, researchers can point to the 116 
earliest cognitive changes in preclinical AD by detecting the point in time at which the slope 117 
of decline in a neuropsychological task becomes steeper in future AD patients than in stable 118 
healthy participants (16-18). 119 
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In the past fifteen years, research on the predementia stage of Alzheimer’s disease has 120 
particularly focused on people with MCI. Initial criteria for MCI were the presence of 121 
subjective memory complaints and objective memory deficits, without other cognitive 122 
impairment, with relatively preserved functioning in daily life and no dementia (19). 123 
However, it soon appeared that MCI is a heterogeneous entity and that the different clinical 124 
MCI subtypes do not have the same prognosis. In particular, a distinction has been made 125 
between the amnestic forms of MCI (aMCI, either single domain if only memory is affected, 126 
or multiple domain if other cognitive functions are also deficient) and non-amnestic forms of 127 
MCI (single-domain or multiple domain) (20). Given that annual rate of progression to AD 128 
among patients with aMCI is much higher than in healthy older people (6.5% versus less than 129 
1%, respectively (21)) whereas non-amnestic MCI patients more frequently progress to non-130 
AD dementia (20), aMCI has been considered as a clinical manifestation of incipient AD or 131 
the prodromal phase of AD. Nevertheless, all aMCI patients are not to develop AD dementia 132 
symptoms. It is therefore necessary to find specific markers that would indicate whether a 133 
patient is likely or not to become demented in the near future. This motivated longitudinal 134 
studies that selected groups of MCI patients either in the community or in clinical settings and 135 
evaluated them regularly until they develop AD or for follow-up periods that typically vary 136 
between 1 year and 4 years. Performance from the initial cognitive assessment is then 137 
retrospectively analyzed to find the measure that best discriminates between MCI patients 138 
who remained stable throughout the follow-up period and those who progressed to AD.  139 
Other studies have also investigated the issue of cognitive markers of AD in other at-140 
risk people, such as carriers of the APOE ε4 allele (see (22) for a review). The current review 141 





Neuropsychological assessments that best predict Alzheimer’s disease 145 
Typically, longitudinal assessments of cohorts of healthy older adults or of patients with Mild 146 
Cognitive Impairment involve a more or less extensive battery of standard neuropsychological 147 
tests. The cognitive domains that are usually evaluated comprise episodic memory (memory 148 
for new information personally experienced in a specific context), working memory (to 149 
maintain a small quantity of information for a very brief period of time), executive functions 150 
(high-order functions that facilitate adaptation to new or complex situations, when highly 151 
practiced cognitive abilities no longer suffice), language and semantic memory (such as fluent 152 
word retrieval), and visuospatial abilities. Comparison between studies is made difficult 153 
because of the variety of tests that have been used, the heterogeneity of the population 154 
investigated (in terms of sample size, characterization of MCI patients, follow-up duration), 155 
the diversity of the cognitive testing (either several memory tests versus only one, the number 156 
of other neuropsychological scores) and the use of different statistical approaches (logistic 157 
regression analyses, survival analyses...). Therefore, only general trends can be drawn from 158 
current research on the earliest sign of cognitive decline in the predementia stage of 159 
Alzheimer’s disease. 160 
Among the cognitive domains that are evaluated with standard neuropsychological 161 
batteries, episodic memory was consistently identified as the first domain to decline in 162 
population-based studies of preclinical Alzheimer’s disease (see Table 1). In the majority of 163 
longitudinal studies of MCI patients, measures of episodic memory also emerge as the best 164 
predictors of progression to AD (23-51). This seems to be true for verbal episodic memory as 165 
well as for visual episodic memory, when the latter is evaluated. The memory decline initiates 166 
many years before the clinical diagnosis of Alzheimer’s disease. For instance, future AD 167 
patients may present with subtle episodic memory deficits compared to stable healthy 168 
individuals for as long as 9 to 10 years before the emergence of the first clinical symptoms 169 
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(13, 15, 52). Furthermore, it has been suggested that, although episodic memory is affected 170 
very early, performance plateaus for several years before showing an abrupt decline 2 or 3 171 
years before dementia onset (53). 172 
 Standard tests of episodic memory consist in presenting a list of items (e.g., words or 173 
pictures) and subsequently evaluating memory for these items by either asking the 174 
participants to recall as many studied items as possible or to identify among propositions 175 
those items that were studied (recognition). For recall tests, participants may have to retrieve 176 
studied items without any support (free recall) or to retrieve studied items on the basis of 177 
some cue, such as the semantic category to which the item belongs (cued recall). Several tests 178 
assess recall immediately after the study phase (immediate recall) and then again after 20 or 179 
30 minutes (delayed recall). Recall measures are more often cited as good cognitive markers 180 
of future AD than recognition scores. Moreover, many population-based studies and MCI 181 
follow-up studies point toward the usefulness of scores of delayed recall as excellent 182 
predictors of progression to AD (12-15, 23, 25, 34, 36, 39, 41, 43, 45, 47, 48, 54-57).  183 
As mentioned above, the question of which memory test and which measure are the 184 
best has currently no definitive answer given the heterogeneity of the tests that have been used 185 
in the different studies. Nevertheless, assuming that the different memory tests do not have 186 
the same sensitivity and specificity, a few studies have tried to compare the predictive 187 
accuracy of several memory tests, in an attempt to find the one that would be particularly 188 
appropriate for identifying early AD among MCI patients (27, 37, 42). The Free and Cued 189 
Selective Reminding test (and its longer versions avoiding ceiling effects in healthy subjects, 190 
the Double Memory test (58) and the RI-48 test in French language (59)) was found to best 191 
discriminate between AD or MCI patients and healthy subjects, and also between MCI 192 
patients who will progress to AD and MCI patients who will remain stable, when compared to 193 
other standard memory tests. In the Free and Cued Selective Reminding test, participants are 194 
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shown 16 items (e.g., grapes) presented four at a time on a card. For each card, the 195 
participants have to point and name aloud each item after its unique category cue (e.g., fruit) 196 
has been provided. When all four items of a card have been identified, immediate cued recall 197 
of those four items is tested. Once all four items have been successfully recalled (or for a 198 
maximum of three trials), the next card is presented following the same procedure until all 16 199 
items have been studied. After a brief retention interval of 20 seconds, three recall trials are 200 
proposed, each consisting of free recall followed by cued recall (e.g., what was the fruit?) for 201 
items that have not been spontaneously recalled. After 30 minutes, free and cued delayed 202 
recall is assessed. The advantage of the Free and Cued Selective Reminding test (and RI48 203 
test) has been explained by the fact that it provides cognitive support at both encoding and 204 
retrieval. Indeed, in these tests, cognitive support consists in controlled encoding of materials 205 
by relating the items to their respective semantic category followed by a cued recall test where 206 
the categories serve as cues. This would facilitate performance of participants whose main 207 
difficulties concern the initiation of memory strategies (e.g., healthy older participants, 208 
demented patients with frontal lesion), but not performance of participants who have genuine 209 
difficulties with memory encoding and storage (e.g., AD patients) (60, 61). Consistently, cued 210 
recall in the Free and Cued Selective Reminding test (as well as Double Memory test and 211 
RI48) is better than free recall in differentiating AD from healthy aging and other forms of 212 
dementia like fronto-temporal dementia, Huntington’s disease or Parkinson’s disease (62). 213 
Building upon these findings, a revision of the research criteria for MCI has been proposed in 214 
order to better define prodromal Alzheimer’s disease (63): an episodic memory deficit taking 215 
the form of “recall deficit that does not improve significantly or does not normalise with 216 
cueing or recognition testing and after effective encoding of information has been previously 217 
controlled” is considered the core diagnostic criteria.  218 
10 
 
The predominance of episodic memory deficits as cognitive markers of incipient 219 
typical AD has been interpreted as reflecting the early pathological involvement of the medial 220 
temporal lobe in the course of Alzheimer’s dementia (64). In line with this view, the cued 221 
recall score of the Free and Cued Selective Reminding test was related to medial temporal 222 
glucose metabolism (65) and total recall score (i.e., free + cued recall) of the Free and Cued 223 
Selective Reminding test was found to correlate with hippocampal volume in patients with 224 
Alzheimer’s disease (66). Also, tasks like Paired Associates Learning and face-name 225 
associative memory, that rely on the hippocampus for encoding relational bounds between 226 
pieces of information (67), have a very good discriminative power for detecting MCI patients 227 
who will develop AD (24, 26, 44). This is consistent with the idea that hippocampus-228 
dependent tasks are sensitive to early cerebral changes in AD. 229 
As stressed by Gainotti et al. (68), in order to propose an operational criteria of the 230 
best neuropsychological predictors of conversion to AD, one needs not only to identify 231 
specific memory tests that are the most efficient predictors, but also to define the most 232 
appropriate cut-off scores for discriminating at-risk individuals. Ideally, stringent cut-off 233 
scores should be used, as stricter measures seem to provide better prediction of conversion 234 
(69). As an illustration, in addition to showing the adequacy of the Free and Cued Selective 235 
Reminding test as predictor of AD, Sarazin et al. (37) proposed a free recall score of 17/48 236 
(corresponding to the sum of free recall scores for the 3 trials) together with a total score over 237 
the three trials of 40/48 as optimal cut-off score to discriminate MCI patients with a high 238 
probability of progressing to AD within 36 months (90%). 239 
Beyond the episodic memory domain, poor verbal fluency performance is put forward 240 
as a good predictor of future AD in several population-based studies (Table 1) and a few MCI 241 
follow-up studies (25, 31, 43, 49). In particular, category verbal fluency (e.g., to provide as 242 
many animals exemplars as possible in 2 minutes) predicts significantly progression to AD 243 
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(12, 14, 15, 17, 52, 70, 71), while phonemic verbal fluency (e.g., to provide as many words 244 
starting with the letter F as possible in 2 minutes) was less frequently identified as a cognitive 245 
marker of Alzheimer’s disease (57, 72). The relative sequence of the decline of episodic 246 
memory and category fluency is controversial, as some studies indicated that memory 247 
impairment arises first (14, 15, 17), while another work reported initial disruption of category 248 
fluency preceding memory decline by a few years (70). Category fluency tasks are multi-249 
determined, involving mainly semantic memory and executive functions like flexibility and 250 
inhibition. So it is not clear whether predementia impairment in these tasks reflect early 251 
emergence of executive or semantic difficulties. In favor of an early executive impairment is 252 
the observation that category fluency has been found to decline together with a measure of 253 
flexibility (Trail Making Test) (14, 17). Moreover, a qualitative analysis of response 254 
production during a category fluency task in individuals who were to develop AD 5 years 255 
later showed that difficulties concerned switching between subcategories during word 256 
production (e.g., to cite farm animals, then insects, birds…) which is an executive ability 257 
rather than accessing many items within one subcategory which measures semantic memory 258 
storage (73). However, given that an executive decline would also affect phonemic fluency, 259 
the semantic account has sometimes been favored (68, 74), notably in light of the severe 260 
semantic memory deficits found in MCI patients (74). Moreover, Wilson et al. (18) suggested 261 
that semantic memory deficits may even precede episodic memory decline in the predementia 262 
period, a finding paralleling the very initial decline of category fluency put forward by 263 
Amieva et al. (70). 264 
Other early neuropsychological predictors of AD have also been described, such as 265 
visuospatial abilities (57, 71, 75), abstract reasoning (13, 52, 70, 76), recognition memory of 266 
objects (48, 77, 78) or short term memory for conjunctions of features (79-81). Even though 267 
controlled episodic memory tests and category fluency tasks emerge as the most discriminant 268 
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measures that allow pointing at future AD patients, most studies found actually that the 269 
predementia stage of AD can involve subtle deficits in a broad range of neuropsychological 270 
tests. Indeed, a combination of cognitive measures often provides greater predictive accuracy 271 
than a single score (15, 26, 28, 38, 49, 50, 82). Thus, in the face of the variety of measures 272 
that was found to be sensitive and specific to early AD, future search for the best predictors 273 
should probably consider combination of tasks assessing episodic memory, semantic memory, 274 
executive functioning, visuospatial processing and abstract reasoning.  275 
 276 
Combining neuropsychology and neuroimaging for prediction of dementia 277 
Current research criteria for MCI due to Alzheimer’s disease (83) and the recent 278 
recommendations for defining preclinical Alzheimer’s disease (84) incorporated biomarkers 279 
like cerebrospinal fluid (CSF) measures of amyloid and tau pathology, medial temporal 280 
atrophy on MRI images and reduction of glucose metabolism in the temporoparietal and 281 
medial posterior cortices or cerebral accumulation of amyloid on PET scans. In this context, it 282 
seems advisable to combine several markers of Alzheimer’s disease as this may improve 283 
prediction accuracy.  284 
 Actually, several studies have reported good predictive power for classifying MCI 285 
patients as future AD versus stable MCI when using combination of neuropsychological 286 
measures and biomarkers (medial temporal atrophy, temporoparietal glucose metabolism, 287 
CSF amyloid, cortical thickness) (see Table 2). Some argued that combining neuroimaging 288 
and neuropsychological markers improved discrimination accuracy compared to each kind of 289 
predictor alone. This was in fact based on mere inspection of classification accuracies. For 290 
instance, Visser et al. (85) used logistic regression analyses to assess the predictive power of a 291 
memory measure and the manually-drawn volume of the medial temporal lobe to classify 292 
subjects with mild cognitive impairment as a function of whether they developed dementia or 293 
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not in a 3-year follow-up period. They observed that the highest classification accuracy was 294 
obtained by combining the memory score and the medial temporal lobe volume (96%). 295 
Memory or cerebral atrophy alone correctly classified respectively 88% and 77% of the 296 
patients. In the same vein, in Schmand et al. (47), combining a verbal episodic memory score, 297 
hippocampal volume and CSF amyloid measure correctly predicted progression from MCI to 298 
AD with an accuracy of 70%, whereas classification accuracy was below 70% for each 299 
individual measure. Similarly, Peters et al. (86) indicated that cortical thickness of the anterior 300 
cingulate gyrus combined to specific memory measures yielded a classification accuracy of 301 
87.5% in the discrimination between stable MCI versus MCI who developed AD. This was 302 
considered more accurate predictions than those based on neuroimaging (75%) or cognitive 303 
measures (82.5%) alone. 304 
 In an attempt to provide support to this observation, we recently assessed the statistical 305 
significance of the improvement in predictive accuracy from individual predictors to 306 
combined markers (87). As hypothesized, combining well-known neuropsychological 307 
markers of AD (RI48 and verbal fluency scores) and measures of cerebral glucose metabolism 308 
(FDG-PET) allowed to discriminate stable and progressor MCI patients significantly better 309 
(89%) than using neuroimaging data alone (74%) (permutation test, p < .001). 310 
 311 
Conclusions 312 
Individuals who will develop Alzheimer’s disease present with specific cognitive difficulties 313 
several years before any clinical sign of pathology are detected. When they exhibit mild 314 
cognitive impairment, it is possible to predict whether they have a high risk of progressing to 315 
the typical form of Alzheimer’s disease (amnesic presentation) on the basis of performance in 316 
some neuropsychological tests. Prediction of AD achieves high sensitivity and specificity for 317 
a measure of verbal cued recall following controlled encoding (Free and Cued Selective 318 
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Reminding test, RI48). This measure is thought to be particularly sensitive to early 319 
hippocampal neuropathological changes in AD and their cognitive consequence, namely a 320 
specific deficit of memory encoding and consolidation, as opposed to a deficit in elaborative 321 
encoding and retrieval strategies like in normal aging and other forms of dementia. Future AD 322 
onset is also well predicted by category verbal fluency scores. These neuropsychological 323 
measures significantly improve predictive accuracy when they are added to neuroimaging 324 
biomarkers. This finding has been incorporated in recent revisions of diagnostic criteria for 325 
the prodromal phase of Alzheimer’s disease (63, 83). Thus, specific neuropsychological 326 
deficits involving encoding of new information into episodic memory and word retrieval into 327 
semantic memory, combined with neuroimaging biomarkers, may allow to point at older 328 
individuals with greater risk to develop Alzheimer’s disease in coming years. Importantly, 329 
these markers alert about an increased probability of dementia, but should not be taken as 330 
definitive sign of future dementia. As stressed in the revised diagnostic criteria, the 331 
combination of neuropsychological profile and biomarkers should be used for research 332 
purposes rather than for the sake of clinical diagnosis. Indeed, one of the main goals of 333 
detecting at risk individuals is the identification of targets for testing therapeutic interventions 334 
that have the potential of attenuating the rate of cognitive decline, such as individualized 335 
cognitive rehabilitation programs or modification of lifestyle, including nutritional 336 
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Figure  captions. 636 
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Figure 1. Selection of reports included in the review.  638 
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Table 1. Population-based longitudinal studies testing for the cognitive measures that predict 640 
future development of Alzheimer’s disease. 641 
Study Cohort name N Follow-up 
duration 
Earlier emerging cognitive 
impairments 




317 (64) 4 years Verbal and visual episodic 
memory, working memory, 
category fluency (2 years 
before diagnosis) 




1045 (55) 13 years Verbal episodic memory, 
working memory 








al. (1997) (54) 
 139 (16) 5 years Verbal episodic memory 
(2.8 years before 
diagnosis) 




205 (26) 3 years Verbal and visual episodic 
memory; phonemic 
fluency (3 years before 
diagnosis) 




532 (73) 6 years Verbal episodic memory (6 
years before diagnosis) 






22 years Verbal episodic memory 
and abstract reasoning (10 
years before diagnosis) 
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264 (32) 10 years Verbal episodic memory (5 
years before diagnosis) 






603 (120) 10 years Verbal episodic memory, 
executive function (1.5 
year before diagnosis) 






551 (68) 10 years Verbal episodic memory 
and executive function 
(decline between 3.5 and 
1.5 years before 
diagnosis)* 




488 (75) 19 years Verbal episodic memory 
(7-8 years before 
diagnosis); Performance 
IQ (2 years before 
diagnosis)* 




120 (15) 6 years Verbal episodic memory (6 
years before diagnosis) 




693 (72) 8 years Verbal and visual episodic 
memory (5-8 years before 
diagnosis); category 
fluency and executive 
function (3.5-5 years 
before diagnosis) 
Rapp et al. Berlin Aging 187 (15) 4 years Attention, executive 
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(2005) (91) Study function, verbal episodic 
memory 
Tierney et al. 
(2005) (15) 
Canadian Study 






5 and 10 years 5 years before diagnosis: 
verbal episodic memory, 
category fluency, 
information. 
10 years before diagnosis: 
verbal episodic memory 




9 years Visual episodic memory, 
category fluency, abstract 
reasoning, global cognition 
(9 years before diagnosis)* 




14 years Category fluency; abstract 
reasoning (12 years before 
diagnosis)* 




Study of Aging 
1006 (92) 15 years Verbal episodic memory (7 
years before diagnosis); 
executive function (2-3 
years before diagnosis)* 
Johnson et al. 
(2009) (92) 
 444 (134) 25 years Visuospatial function (3 
years before diagnosis), 
global cognition (2 years), 
memory (1 year)* 
Auriacombe et 
al. (2010) (93) 
3C study 1160 (60) 5 years Verbal episodic memory 
33 
 
Wilson et al. 
(2011) (18) 
Religious Orders 






16 years Semantic memory, 
working memory (6 years 
before diagnosis)* 
Riley et al. 
(2011) (71) 
UK-ADC 121 (32) 7.5 years Constructional praxis, 
verbal episodic memory, 
category fluency* 




627 (48) 12 years Verbal episodic memory 
Schmid et al. 
(2013) (57) 
BASEL 825 (29) 13 years Verbal and visual episodic 
memory, verbal fluency, 
visuospatial ability 
N. Number of participants (number of progression to AD). AD. Alzheimer’s disease.  642 
* Analysis of change point (time at which the rate of decline changes).  643 
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Table 2. Predictive accuracy of cognitive measures, neuroimaging or CSF biomarkers, and 644 
combination of markers for detecting progression to AD in longitudinal studies of MCI 645 
patients. 646 




Visser et al. 
(1999) (85)  
27 (9) 3 years - Episodic memory 
- MRI 




Arnaiz et al. 
(2001) (75) 
20 (9) 3 years - Visuospatial ability 
- FDG-PET 





Borroni et al. 
(2006) (95)  




al. (2008) (82)  
148 (39) 3 years - Neuropsychology battery 
- MRI 




Gomar et al. 
(2011) (96) 
320 (116) 2 years - Neuropsychology battery 
+ MRI 
71.9 % 
Venneri et al. 
(2011) (97) 
25 (11) 3 years Neuropsychology battery + 
MRI 
Sensitivity 91 % 
Schmand et al. 
(2012) (47) 










- Neuropsychology + MRI 
+ CSF 
- Neuropsychology + MRI 




Peters et al. 
(2014) (86) 
40 (18) 2 years - Neuropsychology battery 
- MRI 




Segovia et al. 
(2014) (87) 
46 (26) 3 years - Neuropsychology battery 
- FDG-PET 





N. Number of MCI patients (number of patients who progressed to AD). MRI. Measure of 647 
cerebral grey matter volume or cortical thickness. FDG-PET. Measure of cerebral glucose 648 
metabolism. SPECT. Measure of cerebral perfusion. CSF. Measure of tau and Aβ1-42 levels 649 
in CSF. 650 
  651 
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 652 
